Original Articles: Bladder Cancer: Neoadjuvant Cisplatin Chemotherapy Before Radical Cystectomy in Invasive Transitional Cell Carcinoma of the Bladder: A Prospective Randomized Phase III Study

Martínez-Piñeiro, J A; Martín, M. González; Arocena, Fernando; Flores, Nicolás; Roncero, Carlos Ramos; Portillo, J.A.; Escudero, A; Cruz, F. Jiménez; Isorna, Santiago

doi:10.1016/s0022-5347(01)67614-6

Cited by 152 publications

(56 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The relative death risk for patients who received chemotherapy local relapse rate is similar to the 18% rate noted in a recent series after treatment with cystectomy only and was 0.69 (range 0.49-0.98) compared to that for the control group after adjustment for T category. Other factors equivalent follow-up [7], and the 18% rate noted in another randomized trial [8]. Median interval to local retested were not significant in this analysis.…”

Section: Resultsmentioning

confidence: 61%

Nordic Prospective Trials of Radical Cystectomy and Neoadjuvant Chemotherapy

et al. 1998

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 61%

Nordic Prospective Trials of Radical Cystectomy and Neoadjuvant Chemotherapy

et al. 1998

View full text Add to dashboard Cite

“…The existence of polymorphism at codon 31 in thep21 gene, homozygous and heterozygous AGC (Ser) and/or AGA (Arg) have been reported elsewhere (Li et al, 1995;Shiohara et al, 1994). Using samples having these 3 types of polymorphism as a control, p21-gene mutations were examined by PCR-SSCP analysis.…”

Section: Results P21 S T a T U In 4 Bladder-cancer Cell Linesmentioning

confidence: 72%

“…and inhibits DNA replication through its physical interaction with PCNA (Waga et al, 1994;Xiong et al, 1993). Thus, p21 may be a putative tumorsuppressor gene, but p21 mutations have been reported to be rare in human canccr (Bhatia et al, 1995;Gao et al, 1995;Li et al, 1995;Shiohara et al, 1994;Watanabe et al, 1995). In addition, both GI arrest and apoptosis can occur without activation of either p53 or p21, and the exact role of p2Z in apoptosis is not fully known (El-Deiry et al, 1994;Steinman et al, 1994).…”

mentioning

confidence: 99%

Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines withp21/WAF1/CIP1 and/orp53 gene alterations

et al. 1996

View full text Add to dashboard Cite

The p53‐inducible cyclin‐dependent kinase inhibitor, p21/WAF1/CIPI (p21), plays a pivotal role in the G1 arrest or apoptosis of cells exposed to genotoxic stimuli. To determine whether p21 is a putative tumor‐suppressor gene, p21 status was investigated in 4 human bladder‐cancer cell lines of known p53 status. A p21‐gene mutation, one base‐pair insertion at codon 20 resulting in a chain‐termination change at codon 35, was observed in one cell line, HT1376, suggesting structural or functional alteration of the p21 protein. When exposed to DNA‐damaging agents, cisplatin or mitomycin C, apoptosis was induced in RT4 with the wild‐type (wt) p53/wt p21, whereas T24 with the p53 non‐sense mutation/wt p21 was resistant. Of the other 2 cell lines with the p53 mis‐sense mutation, apoptosis was induced in SCaBER with the wt p21, but HT1376 with the p21 frame‐shift mutation was fairly resistant. These findings suggest that not only p53 alteration, but also p21 alteration, is important to prevent apoptosis induced by DNA‐damaging agents. When exposed to these agents, p53 and p21 expression was increased in RT4, and not induced in T24. p53 was not induced, but p21 expression was increased in SCaBER, whereas p53 expression was increased but p21 expression was absent in HT1376. Thus, p21 expression itself may have an important role in the induction of apoptosis by DNA‐damaging agents. © 1996 Wiley‐Liss, Inc.

show abstract

“…Subsequently, 39 studies were excluded, including 16 single-arm studies, eight studies with irrelevant study design, five articles with irrelevant outcome, four articles with duplicated study population and six articles without full-text. Fourteen studies were included in the meta-analysis [20][21][22][23][24][25][26][27][28][29][30][31][32][33].…”

Section: Literature Search and Study Characteristicsmentioning

confidence: 99%

Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis

Niu

et al. 2017

CIM

View full text Add to dashboard Cite

Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis Abstract Purpose: Cisplatin-based neoadjuvant chemotherapy (NAC) has been shown to improve survival in patients with muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy as compared with patients who underwent surgery alone. It has also been suggested as current standard of care in surgically-fit patients with MIBC. This meta-analysis assessed the effect of cisplatin-based NAC on survival in patients with bladder cancer.Source: PubMed, CENTRAL, and Embase were searched until November 22, 2016. Two-arm randomized controlled trials that compared cisplatin-based neoadjuvant chemotherapy plus local treatment versus the same local treatment without neoadjuvant chemotherapy were selected. Patients with histologically-confirmed bladder cancer (adenocarcinoma, transitional, or squamous-cell carcinoma) were included. The primary outcome was overall survival (OS).Principal findings: Of the 292 articles initially identified, 14 were included in the final analysis. Patients in the NAC group had similar OS as the local treatment (i.e., radiation therapy or cystectomy) group (pooled hazard ratio [HR] = 0.92, 95% confidence interval [CI]: 0.84 to 1.00, P=0.056). No difference in progress-free survival between two groups was observed (P=0.725). Subgroup analysis showed that OS was similar in patients treated with NAC plus radiotherapy or cystectomy compared with patients who received local treatment alone.Conclusions: Platinum-based NAC was associated with similar survival benefit as patients undergoing cystectomy and/or radiotherapy. No conclusion can be drawn about the optimal platinum-based combination to be used in the neoadjuvant setting.

show abstract

Original Articles: Bladder Cancer: Neoadjuvant Cisplatin Chemotherapy Before Radical Cystectomy in Invasive Transitional Cell Carcinoma of the Bladder: A Prospective Randomized Phase III Study

Cited by 152 publications

References 16 publications

Nordic Prospective Trials of Radical Cystectomy and Neoadjuvant Chemotherapy

Nordic Prospective Trials of Radical Cystectomy and Neoadjuvant Chemotherapy

Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines withp21/WAF1/CIP1 and/orp53 gene alterations

Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis

Contact Info

Product

Resources

About